Latest / WTR Small-Cap Spotlight
eXoZymes (EXOZ): Can Cell-Free Biomanufacturing Deliver at Commercial Scale?
Send us Fan Mail
In this episode, Robert Sassoon, Managing Director and healthcare analyst at Water Tower Research, joins host Tim Gerdeman to discuss his newly published initiation of coverage on eXoZymes (Nasdaq: EXOZ) and its cell-free biomanufacturing platform.
Robert Sassoon explains how the technology works, the significance of the reported 10-fold productivity improvement in NCT manufacturing, and the next steps toward validating commercial-scale production with CDMO partner Curia Global. The conversation also covers NCT’s potential in the nutraceutical market, the competitive…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.